News | October 26, 2022
Novartis maintains growth momentum; Confirms FY’22 Group guidance
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
Philips Foundation and RAD-AID International leverage Philips’ expertise in mobile ultrasound services to improve access to virtual care in hard-to-reach areas
Proceeds from the proposed issue will be utilized to part finance Balaxi’s planned EU GMP-compliant manufacturing facility for Oral Solid Dosages and Liquid Injectables at TSIIC Pharma Formulations SEZ
Hello Patients provides healthcare billing and patients’ management solution
NATCO to sell 15% of shareholding in Nativita for euro 3,45,000 to Pharmasyntez-Nord
Complaints to be filed in both United States and Germany alleging that Pfizer and BioNTech's COVID-19 vaccine Comirnaty unlawfully infringes patents Moderna filed between 2010 and 2016
The company is relieving all its staff who were directly engaged by our US subsidiary in its plant in connection with the manufacturing process in a phased manner
This biopharmaceutical facility is one most significant private sector investment ever in the Middletown region
ELCYS is the only FDA-approved cysteine hydrochloride injection on the market for use as an additive to amino acid solutions
All claims made by Seagen regarding Daiichi Sankyo antibody drug conjugates are denied
Subscribe To Our Newsletter & Stay Updated
